Adaptimmune Therapeutics plc has reached a settlement and release agreement with The University of Texas M.D. Anderson Cancer Center, resolving litigation related to a Strategic Alliance Agreement between the two parties. The litigation, initiated by MD Anderson, claimed over $21 million in damages due to an alleged breach of contract by Adaptimmune. In addition to breach of contract, MD Anderson pursued alternative actions for quantum meruit, promissory estoppel, unjust enrichment, negligent misrepresentation, and reformation. To avoid the costs, risks, and uncertainties of ongoing litigation, both parties agreed to the settlement, which involves a financial payment to MD Anderson. The settlement agreement will lead to the release and dismissal of all claims once MD Anderson receives the full payment. Adaptimmune has stated that the financial obligations under this settlement are not considered material to the company and are not expected to have a significant impact on its financial position or operational results.